RANCAD
Phase 3Small molecule
RANCAD is one of 38 small molecule programs targeting Angina Pectoris. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
69 competitors in Angina Pectoris
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Brilinta
AstraZenecaApproved
Uloric
TakedaApproved
Multaq
SanofiApproved
Isordil
AstraZenecaApproved
Thalitone
Alnylam PharmaceuticalsApproved
Plavix
SanofiApproved
Diabeta
PfizerApproved
Adenocard
AstellasApproved
Nitrostat
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RANCAD. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTSH Biopharm Corporation Limited